Lack Of Off-Label Causation Analysis Could Be Costly
In the past few years, the use of prescription drugs for off-label indications has created legal risk for many pharmaceutical companies. Between 2004 and 2010, the federal government collected $8 billion...To view the full article, register now.
Already a subscriber? Click here to view full article